泮托拉唑三联疗法治疗消化性溃疡的疗效观察

目的 探讨泮托拉唑、克拉霉素及铝碳酸镁三联疗法治疗消化性溃疡的临床疗效及不良反应.方法 选择2009年1月-2010年12月126例十二指肠球部溃疡合并幽门螺杆菌(HP)感染患者,并随机分为观察组和对照组各63例,观察组给予泮托拉唑、克拉霉素及铝碳酸镁三联疗法治疗7 d后,继续单服用泮托拉唑3周.对照组给予奥美拉唑、克...

The efficacy of pantoprazole-based triple therapy for peptic ulcer

Objective To explore the efficacy of triple therapy with pantoprazole, clarithromycin, and hydrotalcite for peptic ulcer and the therapy-related adverse reactions. Methods 126 patients with duodenal ulcer due to H. pylori infection were randomly assigned to receive triple therapy with pantoprazole, clarithromycin, and hydrotalcite for seven days and then pantoprazole alone for three weeks(study group, 63 patients), or triple therapy with omeprazole, clarithromycin, and amoxicillin for seven days and then omeprazole alone for three weeks(control group, 63 patients). Four weeks after treatment, gastroscopy and H. pylori detection were performed to assess the efficacy in both groups. Results The ulcer healing rate and eradication rate did not differ significantly between the study group and the control group(93.65% vs. 90.48% and 95.24% vs. 88.89%, P ＞ 0.05). The incidence rate of adverse reactions was higher in the control group than in the study group(P ＜ 0.05). Conclusions Pantoprazolebased triple therapy is a safe, reliable protocol for peptic ulcer and H. pylori eradication, and has a higher eradication rate and fewer adverse reactions.